SCHEMBL30947952

SCHEMBL30947952

O=C1C(=O)N(C23CC(C2)C3)CCN1Cc1cnc(-c2ccccc2)cn1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IL4I1 Q96RQ9 7/20 0.71
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
PRMT5 O14744 1/20 0.38
HSD11B1 P28845 1/20 0.33
TNIK Q9UKE5 2/20 0.33
DHPS P49366 1/20 0.32
LMNA P02545 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
NPY5R Q15761 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
NEK2 P51955 1/20 0.31
MET P08581 1/20 0.31
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30948269 0.85 IL4I1 (0.69) IL4I1PRMT5HSD11B1TNIK
SCHEMBL30948031 0.84 IL4I1 (0.68) IL4I1CYP11B1CYP11B2PRMT5TNIK
SCHEMBL30947973 0.83 IL4I1 (1.00) IL4I1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL27163434 0.81 IL4I1 (0.62) IL4I1HSD11B1TNIKDHPSSMN1; SMN2
SCHEMBL30947994 0.80 IL4I1 (0.53) IL4I1HSD11B1
SCHEMBL30947916 0.80 IL4I1 (0.61) IL4I1CYP11B1TNIKDHPSNPSR1
SCHEMBL30948291 0.78 IL4I1 (0.65) IL4I1LMNASMN1; SMN2MEN1NPC1
SCHEMBL30948147 0.77 IL4I1 (0.50) IL4I1HSD11B1
SCHEMBL30948375 0.77 IL4I1 (0.64) IL4I1CYP11B1CYP11B2LMNASMN1; SMN2
SCHEMBL30947930 0.76 IL4I1 (0.62) IL4I1CYP11B1CYP11B2PRMT5LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246937-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246937-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 IL4I1 1/4885CYP11B1 1150/4885CYP11B2 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.